Developing innovative therapies that bring new hope to patients with dilated cardiomyopathy (DCM) — that is the mission of CardioGenix.
Shaping the Future of
Cardiomyopathy
Development Pipeline
CardioGenix LLC is accelerating the development of therapeutics for hereditary Dilated Cardiomyopathy (DCM) through ongoing collaboration with LTT Bio-Pharma. Utilizing our proprietary TNNT2 ΔK210 DCM mouse models, we are systematically conducting preclinical evaluations of both efficacy and safety.
Our Strategic Approach
-
Efficacy evaluation using proprietary TNNT2 ΔK210 knock-in DCM mouse models.
-
Simultaneous measurement of cardiomyocyte contractile function and intracellular Ca²⁺ using the IonOptix system.
-
Efficient drug development strategy focused on new indication discovery for approved drugs.
-
By integrating these technologies, we target the root cause of hereditary DCM: reduced myocardial Ca²⁺ sensitivity.
Future Objectives
-
Continuation of preclinical trials and robust data accumulation.
-
Preparation for future Investigational New Drug (IND) applications.
-
Strengthening strategic partnerships to achieve commercialization.*Specific timelines are subject to change based on research progress and funding availability.
*Specific timelines are subject to change based on research progress and funding availability.
Strategic Partnership with LTT Bio-Pharma
We maintain active joint research under the cooperation of LTT Bio-Pharma. By merging our technology with their strategic expertise, we aim for efficient and steady pharmaceutical development.
Interested in Our Work
We welcome inquiries from pharmaceutical companies, investors, and researchers interested in collaboration.